Objective. To assess the potential for genetic influences on sertraline treatment efficacy for depression of Alzheimer disease (dAD). Four functional genetic variants were studied: 2 serotonin receptors (HTR2A-T102C and HTR2C-Cys23Ser), the serotonin transporter (5HTT-LPR), and brain-derived neurotrophic factor (BDNF-Val66Met). Treatment response by genotype was measured by (1) the modified Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change, (2) the Cornell scale for Depression in Dementia, and (3) remission of depression. Methods. We utilized data from the Depression in Alzheimer’s Disease Study 2 (DIADS-2), a 24-week, randomized, multicenter trial showing no significant treatment effect of sertraline on dAD. Proportional odds logistic regression and mixed effects models were used to examine the above mentioned outcome measures. Results. No significant interactions were seen between any of the genetic polymorphisms and the selected outcomes above at 12 or 24 weeks. Discussion. Treatment outcomes in the DIADS-2 trial were not significantly influenced by genetic variation at the loci that were assessed. Future studies should continue to examine the interaction of depression-related genetic variants with antidepressant treatment in Alzheimer disease patients with depression.
RabinsPVLyketsosCGSteeleCD. Practical Dementia Care. 2nd ed. New York, NY: Oxford University Press; 2006.
2.
LyketsosCGLopezOJonesBFitzpatrickALBreitnerJDeKoskyS. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002; 288(12): 1475–1483.
3.
SteinbergMShaoHZandiP. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache county study. Int J Geriatr Psychiatry. 2008; 23(2): 170–177.
4.
LeeHBLyketsosCG. Depression in Alzheimer's disease: heterogeneity and related issues. Biol Psychiatry. 2003; 54(3): 353–362.
5.
RosenbergPBOnyikeCUKatzIR. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'. Int J Geriatr Psychiatry. 2005; 20(2): 119–127.
6.
OlinJTKatzIRMeyersBSSchneiderLSLebowitzBD. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002; 10(2): 129–141.
7.
LyketsosCGDelCampoLSteinbergM. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003; 60(7): 737–746.
8.
LyketsosCGSheppardJMSteeleCD. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Am J Psychiatry. 2000; 157(10): 1686–1689.
9.
MagaiCKennedyGCohenCIGombergD. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry. 2000; 8(1): 66–74.
10.
PetraccaGMChemerinskiEStarksteinSE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr. 2001; 13(2): 233–240.
11.
ReiflerBVTeriLRaskindM. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry. 1989; 146(1): 45–49.
12.
RothMMountjoyCQAmreinR. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry. 1996; 168(2): 149–157.
13.
MartinBKFrangakisCERosenbergPB. Design of depression in Alzheimer's disease study-2. Am J Geriatr Psychiatry. 2006; 14(11): 920–930.
14.
RosenbergPBDryeLTMartinBK. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010; 18(2): 136–145.
15.
WeintraubDRosenbergPBDryeLT. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010; 18(4): 332–340.
16.
DryeLTMartinBKFrangakisCE. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study +/− 2 (DIADS-2)?Int J Geriatr Psychiatry. 2010; 26(6): 573–583.
17.
DurhamLKWebbSMMilosPMClaryCMSeymourAB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl). 2004; 174(4): 525–529.
18.
NgCHEastealSTanSSchweitzerIHoBKAzizS. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(5): 953–957.
19.
HwangJPTsaiSJHongCJYangCHLirngJFYangYM. The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiol Aging. 2006; 27(12): 1834–1837.
20.
TsaiSJChengCYYuYWChenTJHongCJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet. 2003; 123B(1): 19–22.
21.
WilkoszPAKodavaliCWeamerEA. Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2007; 144B(8): 1054–1062.
22.
LappalainenJLongJCVirkkunenMOzakiNGoldmanDLinnoilaM. HTR2C Cys23Ser polymorphism in relation to CSF monoamine metabolite concentrations and DSM-III-R psychiatric diagnoses. Biol Psychiatry. 1999; 46(6): 821–826.
23.
RamanathanSGlattSJ. Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. Am J Geriatr Psychiatry. 2009; 17(10): 839–846.
24.
SerrettiABenedettiFZanardiRSmeraldiE. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(6): 1074–1084.
25.
BorroniBGrassiMArchettiS. BDNF genetic variations increase the risk of Alzheimer's disease-related depression. J Alzheimers Dis. 2009; 18(4): 867–875.
26.
TaylorWDMcQuoidDRAshley-KochA. BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics J. 2011; 11(2): 146–154.
27.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2000.
28.
FolsteinMFFolsteinSEMcHughPR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3): 189–198.
29.
Alzheimer's Association. Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators. Alzheimer Dis Assoc Disord. 2004; 18(3): 171–175.
30.
SchneiderLSOlinJTDoodyRS. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. Alzheimer Dis Assoc Disord. 1997; 11(suppl 2): 22.
31.
AlexopoulosGSAbramsRCYoungRCShamoianCA. Cornell scale for depression in dementia. Biol Psychiatry. 1988; 23(3): 271–284.
32.
CummingsJLMegaMGrayKRosenberg-ThompsonSCarusiDAGornbeinJ. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44(12): 2308.
33.
ObachRSCoxLMTremaineLM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005; 33(2): 262.
34.
SchwabMKaschkaWPSpinaE. Pharmacogenetics in Psychiatry: S. Karger AG; 2010.
